DOJ Medical Marijuana Rule Faces New Legal Challenge

A new lawsuit challenges the DOJ's interpretation of congressional spending restrictions on medical marijuana enforcement.

The challenge, filed May 29, 2026, targets the Justice Department's final rule implementing the Rohrabacher-Farr amendment (now the Blumenauer-McClintock-Norton amendment), which bars DOJ from using federal funds to prevent states from implementing their own medical cannabis laws. The rule, published in final form in early 2026, drew immediate criticism from industry advocates who argued it carved out too many enforcement loopholes.

Law360 didn't disclose the plaintiff's identity or specific legal arguments. But the timing suggests coordinated pushback from either state governments or cannabis operators facing federal scrutiny despite state compliance.

The DOJ rule narrows protections by requiring strict state-law compliance and excluding certain categories of conduct.

The final rule—published after a lengthy notice-and-comment period—defines "implementing" state medical marijuana laws narrowly. It excludes conduct that violates state regulations, even if the operator holds a state license, and maintains that the rider doesn't protect diversion, interstate commerce, or sales to minors.

Critics argue this interpretation guts the rider's intent. If a state-licensed dispensary commits a minor regulatory violation—say, a labeling error or late filing—the DOJ's position is that the Rohrabacher-Farr bar no longer applies, opening the door to federal prosecution. That's a significant expansion of enforcement discretion compared to prior DOJ guidance, which focused on "serious" violations of state law.

The rule effectively transforms the congressional spending restriction into a conditional safe harbor, rather than a blanket bar on interference with state programs.

The challenge arrives as DEA rescheduling and SAFER Banking stall, leaving medical operators in legal limbo.

The lawsuit's timing isn't accidental. DEA's rescheduling proposal remains stalled in administrative review, and the SAFER Banking Act has failed to advance in the Senate despite bipartisan House passage. Medical cannabis operators—especially those in states like California, Colorado, and Michigan with mature regulatory frameworks—are caught between state compliance costs and federal enforcement risk.

For operators, the stakes are existential. A narrow reading of Rohrabacher-Farr means that any state-law misstep—however technical—could trigger asset forfeiture, criminal indictment, or civil penalties under the Controlled Substances Act. Uncertainty chills investment. It complicates banking relationships. And it forces operators into costly over-compliance.

The rule's fate hinges on judicial deference to agency interpretation versus congressional intent.

The legal question is whether courts will defer to DOJ's restrictive reading of the rider or apply a broader interpretation aligned with Congress's stated purpose: to stop federal interference in state medical marijuana programs. Under the major questions doctrine and recent Supreme Court skepticism toward administrative overreach, the plaintiff may argue that DOJ is rewriting a spending restriction into a regulatory scheme without clear statutory authority.

DOJ will likely defend the rule as a reasonable interpretation of ambiguous statutory language. The rider says DOJ can't use funds to "prevent" states from "implementing" their laws—but it doesn't define "implementing," leaving room for the agency to distinguish between lawful state activity and conduct that violates state rules.

Previous litigation over the rider has produced mixed results. In United States v. McIntosh (9th Cir. 2016), the Ninth Circuit held that the rider bars prosecution of defendants who were in strict compliance with state law, but it didn't foreclose enforcement against those who violated state regulations. The new challenge may seek to narrow or overturn that precedent.

Enforcement variance across federal districts will continue regardless of the rule's outcome.

Even if the rule survives judicial review, enforcement will remain uneven. U.S. Attorneys retain prosecutorial discretion, and districts with conservative leadership have continued to bring cases against state-licensed operators, citing diversion or regulatory noncompliance. Districts in the West and Northeast have largely adopted a hands-off posture toward compliant medical programs.

For full background on this story, see the CannIntel topic hub on the DOJ Medical Marijuana Rule.

The practical result: operators in states like Oklahoma or Montana face higher federal risk than those in Oregon or Massachusetts, despite identical state-law compliance. That patchwork creates competitive distortions and forces multistate operators into state-by-state risk assessments that account for both state regulatory strictness and local federal enforcement culture.

The next signal will be the plaintiff's opening brief and DOJ's motion to dismiss. Expect discovery to focus on the rulemaking record and whether DOJ considered less restrictive interpretations. A ruling could take 12-18 months, but interim relief—such as a preliminary injunction blocking enforcement under the narrowed rule—is possible if the plaintiff demonstrates irreparable harm and likelihood of success on the merits.